The Prognostic and Predictive Utility of CDX2 in Colorectal Cancer
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25168673 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Wei Yen Chan und 10 weiteren Autor:innen. Beteiligte Einrichtung: Liverpool Cancer Therapy Centre, Liverpool Hospital, Liverpool, NSW 2170, Australia. Hauptthemen laut MEDLINE: CDX2 Transcription Factor, Colorectal Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Caudal type homeobox transcription factor 2 (CDX2) is a gastrointestinal cancer biomarker that regulates epithelial development and differentiation. Absence or low levels of CDX2 have been associated with poor prognosis and proposed as a chemotherapy response predictor. Tumour tissue samples from 668 patients with stage I–IV colorectal cancer were stained for CDX2 and stratified into two subgroups according to expression levels. Statistical tests were used to evaluate CDX2’s relationship with survival and chemotherapy response. Of 646 samples successfully stained, 51 (7.9%) had low CDX2 levels, and 595 (92.1%) had high levels. Low CDX2 staining was associated with poor differentiation and the presence of lymphovascular or perineural invasion and was more common in colon and right-sided tumours. Overall survival (p < 0.001) and disease-free survival (p = 0.009) were reduced in patients with low CDX2 expression. Multivariable analysis validated CDX2 as an independent poor prognostic factor after excluding confounding variables. There was no statistically significant improvement in survival with adjuvant chemotherapy in stage II colon cancer (p = 0.11). In the rectal cohort, there was no relationship between CDX2 levels and therapy response. While confirming the prognostic utility of CDX2 in colorectal cancer, our study highlights that larger studies are required to confirm its utility as a predictive chemotherapy biomarker, especially in left-sided and rectal cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Liverpool Cancer Therapy Centre, Liverpool Hospital, Liverpool, NSW 2170, Australia.
- School of Medicine, Western Sydney University, Locked Bag 1797, Penrith, NSW 2571, Australia.
- Ingham Institute for Applied Medical Research, Liverpool, NSW 2170, Australia.
- Department of Anatomical Pathology, Liverpool Hospital, Liverpool, NSW 2170, Australia.
- Macarthur Cancer Therapy Centre, Campbelltown Hospital, Campbelltown, NSW 2560, Australia.
- Faculty of Medicine, South Western Sydney Clinical School, The University of New South Wales, Liverpool, NSW 2170, Australia.
ORCID-Profile: Wei Yen Chan, Tara Laurine Roberts, Therese Maria Becker, Weng Ng, Stephanie Hui-Su Lim
Zitieren
APA
Chan, W. Y., Chua, W., Wilkinson, K., Epitakaduwa, C., Mandaliya, H., Descallar, J., Roberts, T. L., Becker, T. M., Ng, W., Lee, C. S., & Lim, S. H. (2024). The Prognostic and Predictive Utility of CDX2 in Colorectal Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25168673
Vancouver
Chan WY, Chua W, Wilkinson K, Epitakaduwa C, Mandaliya H, Descallar J, et al. The Prognostic and Predictive Utility of CDX2 in Colorectal Cancer. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25168673
BibTeX
@article{Chan2024,
author = {Chan, Wei Yen and Chua, Wei and Wilkinson, Kate and Epitakaduwa, Chandika and Mandaliya, Hiren and Descallar, Joseph and Roberts, Tara Laurine and Becker, Therese Maria and Ng, Weng and Lee, Cheok Soon and Lim, Stephanie Hui-Su},
title = {The Prognostic and Predictive Utility of CDX2 in Colorectal Cancer},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25168673}
}
EUVIMED